Skip to main content
SpringerLink
Log in

Impact of CYP2C19 polymorphisms on the clinical action of proton pump inhibitors (PPIs)

  • Editorial Commentary
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kirchheiner J, Fuhr U, Brockmöller J (2005) Pharmacogenetics-based therapeutic recommendations-ready for clinical practice. Nat Rev Drug Discovery 4:639–647

    Article  CAS  Google Scholar 

  2. Lou H-Y, Chang C-C, Sheu M-T, Chen Y-C, Ho H-O (2008) Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism. Eur J Clin Pharmacol (in press)

  3. Klotz U, Schwab M, Treiber M (2004) CYP2C19 polymorphism and proton pump inhibitors. Basic Clin Pharmacol Toxicol 95:2–8

    PubMed  CAS  Google Scholar 

  4. Klotz U (2006) Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Int J Clin Pharmacol Ther 44:297–302

    PubMed  CAS  Google Scholar 

  5. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M (2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79:103–113

    Article  PubMed  CAS  Google Scholar 

  6. Junghard O, Hassan-Alin M, Hasselgren G (2002) The effect of the area under the plasma concentration vs time curve and the maximum plasma concentration of esomeprazole on intragastric pH. Eur J Clin Pharmacol 58:453–458

    Article  PubMed  CAS  Google Scholar 

  7. Shi S, Klotz U (2008) Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol 64:935–951

    Google Scholar 

  8. Schwab M, Klotz U, Hofmann U, Schaeffeler E, Leodolter A, Malfertheiner P, Treiber G (2005) Esomeprazole-induced healing of gastrooesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data. Clin Pharmacol Ther 78:627–634

    Article  PubMed  CAS  Google Scholar 

  9. Horn J (2004) Review article: relationship between the metabolism and efficacy of proton pump inhibitors-focus on rabeprazole. Aliment Pharmacol Ther 20(suppl 6):11–19

    Article  PubMed  CAS  Google Scholar 

  10. Sugimoto M, Furuta T, Shirai N, Kajimura M, Hishida A, Sakurai MO, Ishizaki T (2004) Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status. Clin Pharmacol Ther 78:290–301

    Article  CAS  Google Scholar 

  11. Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, Aiach M, Lechat P, Gaussen P (2006) Cytochrome P4502C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108:2244–2247

    Article  PubMed  CAS  Google Scholar 

  12. Trenk D, Hochholzer W, Fromm MF, Chialda L-C, Pahl A, Valina CM, Stratz C, Schmiebusch P, Bestehorn HP, Buettner HJ, Neumann F-J (2008) Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 51:1925–1934

    Article  PubMed  CAS  Google Scholar 

  13. Gilard M, Arnaud B, Cornily J-C, Le Gal G, Lacut K, Le Calvez G, Mansourati J, Mottier D, Abgrall J-F, Boschat J (2008) Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin. J Am Coll Cardiol 51:256–260

    Article  PubMed  CAS  Google Scholar 

  14. Gurbel PA, Lau WC, Tantry US (2008) Omeprazole-a possible new candidate influencing the antiplatelet effect of clopidogrel. J Am Coll Cardiol 51:261–263

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The secretarial help of Mrs. U. Hengemühle is highly appreciated. The work was supported by the Robert Bosch Foundation Stuttgart.

Author information

Authors and Affiliations

  1. Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany

    Ulrich Klotz

  2. University of Tübingen, Tübingen, Germany

    Ulrich Klotz

  3. Dr. Margarete Fischer-Bosch-Institut für Klinische Pharmakologie, Auerbachstraße 112, D-70376, Stuttgart, Germany

    Ulrich Klotz

Authors
  1. Ulrich Klotz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ulrich Klotz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Klotz, U. Impact of CYP2C19 polymorphisms on the clinical action of proton pump inhibitors (PPIs). Eur J Clin Pharmacol 65, 1–2 (2009). https://doi.org/10.1007/s00228-008-0571-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-008-0571-x

Search

Navigation